Patient characteristics
| Factor . | Number . |
|---|---|
| Median age | 67 years |
| Range | 29 - 85 years |
| Median follow-up | 6.2 years |
| Required treatment | |
| Treated | 19 |
| Untreated | 26 |
| Binet stage | |
| A | 39 |
| B/C | 6 |
| LDT, months | |
| >12 | 25 |
| <12 | 6 |
| Not determined | 14 |
| CD38 expression | |
| <20% | 26 |
| ≥20% | 19 |
| Not determined | 0 |
| Genetics | |
| Normal | 5 |
| 13q− | 12 |
| 12+ | 2 |
| 11q−/ 17p− | 2 |
| Not determined | 24 |
| IGHV status | |
| <98% | 15 |
| ≥98% | 9 |
| Not determined | 21 |
| Factor . | Number . |
|---|---|
| Median age | 67 years |
| Range | 29 - 85 years |
| Median follow-up | 6.2 years |
| Required treatment | |
| Treated | 19 |
| Untreated | 26 |
| Binet stage | |
| A | 39 |
| B/C | 6 |
| LDT, months | |
| >12 | 25 |
| <12 | 6 |
| Not determined | 14 |
| CD38 expression | |
| <20% | 26 |
| ≥20% | 19 |
| Not determined | 0 |
| Genetics | |
| Normal | 5 |
| 13q− | 12 |
| 12+ | 2 |
| 11q−/ 17p− | 2 |
| Not determined | 24 |
| IGHV status | |
| <98% | 15 |
| ≥98% | 9 |
| Not determined | 21 |
13q−, abnormalities involving loss of chromosome 13q; 12+, trisomy 12; 11q− and 17p−, any fluorescent in situ hybridization or karyotypic abnormality involving chromosome 11q or 17p; <98%, sequence homology with the closest germline sequence; CD38 expression, <20%/≥20% of the CLL B cells expressing the antigen; IGHV status: ≥98% sequence homology with the closest germline sequence; LDT, lymphocyte doubling time <12 months/>12 months; Normal, no detectable cytogenetic aberration by fluorescent in situ hybridization.